| abstract |
FIELD: biotechnology.SUBSTANCE: disclosed is an isolated binding protein which selectively binds to TGFβ1. Said binding protein is dimer scFv-Fc. Also disclosed is use of said binding protein in a pharmaceutical composition for treating human diseases, such as fibrous disease, cancer, diffuse skin system sclerosis, a disease characterized by disturbed bone tissue remodeling, or kidney disease.EFFECT: invention provides selective binding and neutralization of TGFβ1 activity with high affinity and avidity; scFv-Fc dimers are candidates for therapeutic routes of use due to combination of their smaller size, high selectivity, activity with respect to TGFβ1 and prolonged half-life.12 cl, 7 dwg, 3 tbl, 6 ex |